When cancer therapy raises the pressure: predictors of early hypertension with VEGFR inhibitors

Clicks: 1
ID: 323263
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #69 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Hypertension (HTN) is a recognized cardiotoxicity in cancer patients treated with vascular endothelial growth factor receptor inhibitors (VEGFRIs), yet VEGFRI-induced HTN remains poorly characterized. This study evaluated outcomes, predictive factors, and potential protective mechanisms for HTN in patients receiving VEGFRIs. Methods We retrospectively reviewed 290 patients treated with axitinib, cabozantinib, lenvatinib, or pazopanib (2015–2023), analyzing demographics, comorbidities, and antihypertensive management. Patients were stratified by presence of hypertension toxicity (HTN-TOX), defined as initiation or escalation of antihypertensive therapy within 30 days of VEGFRI start. Outcomes included major cardiovascular events and mortality. Multivariable logistic regression identified independent predictors. Results Fifty-nine patients (20%) developed HTN-TOX. Baseline systolic blood pressure was modestly higher in the HTN-TOX group (135±16 vs 130±16 mmHg, p = 0.044) and remained significantly elevated at one month (141±21 vs 132±19 mmHg, p = 0.002). Baseline demographics, comorbidities, and cancer therapy were otherwise similar, with a non-significant trend toward more baseline HTN in the HTN-TOX group (83% vs 74%, p = 0.18). On univariate analysis, HTN-TOX was associated with greater thiazide use (36% vs 19%, p = 0.009) and trended toward higher ACEI/ARB use (63% vs 52%, p = 0.18). Kaplan–Meier survival (p = 0.13) and incidence of stroke, myocardial infarction, or heart failure did not differ. On multivariable analysis, smoking independently predicted risk for HTN-TOX (OR 2.45, 95% CI 1.25–4.88, p = 0.009), while ≥1 baseline antihypertensive was protective (OR 0.27, 95% CI 0.11–0.63, p = 0.003). Conclusion HTN-TOX occurred in one-fifth of patients within 30 days of VEGFRI initiation. Smoking was an independent risk factor, while baseline antihypertensive therapy was protective. These findings support optimizing blood pressure control before VEGFRI therapy and highlight the need for further studies to define preventive strategies and clarify clinical implications. Clinical Implications: VEGFRI-associated hypertension develops quickly and affects a significant subset of patients, underscoring the importance of proactive blood pressure monitoring and management. Identifying smoking as a risk factor and baseline antihypertensive therapy as protective suggests that targeted risk reduction and optimization of antihypertensive regimens before treatment may improve patient safety.Kaplan Meier Survival Analysis Forest Plot of Hypertension Predictors
Reference Key
openalex_W7172252543 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors J Wright, N M Nigel Miller, T S Teonna Sharpe, N P Nooruddin Pracha, N P Najhee Purdy, S A S Sakima A. Smith
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.115
URL
https://doi.org/10.1093/eurheartjsupp/suag097.115
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.